Last reviewed · How we verify
NCT04513561: CONFIMID
Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU and COVID-19
trial in Inflammatory Disease in 921 participants. Completed in 27 August 2020.
27 August 2020
Quick facts
| Lead sponsor | University Hospital, Lille |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 921 |
| Start date | 21 July 2020 |
| Primary completion | 27 August 2020 |
| Estimated completion | 27 August 2020 |
| Sites | 1 location across France |
Conditions studied
- Inflammatory Disease — all drugs for Inflammatory Disease →
- Covid19 — all drugs for Covid19 →
Sponsor
University Hospital, Lille
Who can join
18 and older, any sex, with Inflammatory Disease or Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This questionnaire is distributed via a mailing list (e-mail) of patients treated within the framework of the FHU for pathologies including chronic inflammatory bowel diseases or IBD (Crohn's disease and ulcerative colitis), inflammatory rheumatic diseases (such as rheumatoid arthritis and ankylosing spondylitis), but also asthma, psoriasis, atopic dermatitis as well as systemic autoimmune (such as scleroderma, lupus, angioedema) and neurological (multiple sclerosis) diseases. A two-step analysis will be conducted: impact of lock down(March 17, 2020 - May 11, 2020) and a 2-month assessment of end of lock down (from May 11, 2020) on issues addressing: overall impact, impact on the disease, treatment and follow-up, and access to information related to the epidemic during these periods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04513561
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inflammatory Disease
Currently open trials in the same condition.
- NCT06275477 — 68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases · NA · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
- NCT06476535 — Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy · active not recruiting
- NCT06513507 — A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis. · NA · active not recruiting
- NCT06448052 — Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation · Phase 1, PHASE2 · active not recruiting
Other University Hospital, Lille trials
Trials by the same sponsor.
- NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
- NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
- NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
- NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
- NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04513561 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
- Last refreshed: 15 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04513561.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing